WHO backs Moderna and Oxford Ebola vaccine candidates for testing in DRC’s Tumaini trial, the first efficacy study targeting ...
A systematic review examines the cellular mechanisms, pharmacokinetic limitations, and available clinical evidence for the ...
The results are from a randomised, double-blind, placebo-controlled Phase 2b clinical trial involving 189 adults with ...
Fat fraction, together with clinical endpoints, may support a potential accelerated approval pathway for forazapadin Protocol ...
Attovia Therapeutics (NASDAQ:ATTO) reported 12-week results from a small phase 1b study of its experimental itch treatment ...
Zydus Therapeutics, a subsidiary of Zydus Lifesciences Limited, has announced encouraging results from its Phase 2b clinical ...
Gilead Sciences' primary biliary cholangitis (PBC) therapy, Livdelzi (seladelpar), has been shown to diminish a key marker of ...
Clinical Trials Arena on MSN
Mondego Bio begins Phase Ia trial of oral MB‑388
The trial is assessing single and multiple ascending doses of MB‑388 in healthy volunteers.
InnoCare’s orelabrutinib posts 32.8% durable platelet response in Phase III ITP, topping Sanofi’s rilzabrutinib. NMPA NDA ...
(Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo ...
First patient dosed in Phase 2 Vista PD study evaluating VIM0423,a potential first-in-class daily oral therapeutic, for the treatment of refractory tremor in adults with Parkinson’s disease ...
CytomX Therapeutics earns a Buy rating on strong Varseta-M colorectal cancer data, cash runway, and upside potential. Learn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results